Equities

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)200.00
  • Today's Change-2.50 / -1.23%
  • Shares traded708.00
  • 1 Year change-54.55%
  • Beta-1.6267
Data delayed at least 20 minutes, as of Aug 09 2022 08:29 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. It is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. It may be used alone or in combination with other immune checkpoint molecules.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-17.91m
  • Incorporated2006
  • Employees37.00
  • Location
    Faron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
  • Phone+358 24695151
  • Fax+358 24695152
  • Websitehttps://www.faron.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
C4X Discovery Holdings PLC5.71m-4.72m58.68m46.00--3.86--10.28-0.0207-0.02070.02510.06640.3055--9.62124,087.00-25.27-60.05-27.28-68.5397.3999.28-82.71-237.08---493.000.0192----82.4650.65---13.79--
Eco Animal Health Group Plc101.55m5.57m82.28m207.0014.760.98425.800.81030.08230.08231.501.230.91312.173.60490,584.5011.3110.5515.4013.1449.9348.5312.3814.622.57--0.014547.1946.4617.51109.456.21-30.72-29.40
Futura Medical plc.0.00-4.96m99.33m11.00--10.21-----0.018-0.0180.000.03390.00----0.00-73.87-65.78-93.73-86.83-------6,607.25----0.00-------105.85--123.78--
e-Therapeutics plc477.00k-8.07m108.33m32.00--3.87--227.10-0.0169-0.01690.0010.05440.0217--3.3114,906.25-36.62-37.71-38.29-40.40100.00100.00-1,691.82-1,812.91----0.0239--50.47---119.06--42.31--
Scancell Holdings Plc0.00-8.41m109.04m25.00--4.81-----0.0105-0.01050.000.02780.00----0.00-21.98-48.49-24.78-52.14------------0.2598-------181.09------
Faron Pharmaceuticals Oy0.00-17.91m112.02m37.00--43.78-----0.3531-0.35310.000.04630.00----0.00-196.84-165.50-539.12-391.61-------487,178.90---248.330.5486-------25.16--38.80--
Sareum Holdings Plc0.00-1.81m129.33m6.00--22.77-----0.0273-0.02730.000.08340.00----0.00-48.39-49.67-51.44-54.40-------10,610.04----0.00---100.00---52.18------
Creo Medical Group PLC25.16m-24.60m134.25m290.00--1.83--5.34-0.1487-0.14870.1530.40490.26061.775.3486,762.07-25.48---31.67--46.04---97.75--2.67-69.230.1259--166.85---21.06------
Circassia Group PLC27.90m2.30m147.06m128.0079.662.0121.635.270.00440.00750.0640.17420.29452.662.45217,968.802.43-11.692.80-13.9968.1076.198.24-81.991.58--0.0191--16.743.85108.58---22.16--
Data as of Aug 09 2022. Currency figures normalised to Faron Pharmaceuticals Oy's reporting currency: UK Pound GBX

Institutional shareholders

10.59%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Mar 20222.63m4.76%
Skandinaviska Enskilda Banken AB (Denmark)as of 31 Mar 20222.22m4.02%
Rhenman & Partners Asset Management ABas of 30 Jun 2021500.00k0.91%
Canaccord Genuity Wealth Ltd.as of 31 Mar 2022195.99k0.36%
Aktia Varainhoito Oyas of 31 Oct 2021117.37k0.21%
Henderson Global Investors Ltd.as of 30 Jun 2022100.00k0.18%
Sp-Fund Management Co. Ltd.as of 29 Jul 202250.42k0.09%
BG Fund Management Luxembourg SAas of 30 Jun 202231.74k0.06%
More ▼
Data from 31 Mar 2022 - 29 Jul 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.